After approval, Eli Lilly needs to manufacture enough supply, negotiate insurance coverage, set up distribution, and train healthcare providers on the new drug
Yet, the body's response can vary widely
Published July 13, 2022
Creator Pratley R.E Other Affiliation: AdventHealth Translational Research Institute, Orlando, FL, United States Crowley M.J Other Affiliation: Department of Medicine, Division of Endocrinology, Duke University Medical Center, and Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham, NC, United States Gislum M Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Hertz C.L Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Jensen T.B Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Khunti K Other Affiliation: Diabetes Research Centre, University of Leicester, Leicester, United Kingdom Mosenzon O Other Affiliation: Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel Buse J.B School of Medicine, Department of Medicine Abstract Introduction: The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme
